SCHEMBL4195484

SCHEMBL4195484

C=CC(=O)OC(COc1ccc(OCC(COc2cccc3ccccc23)OC(=O)C=C)cc1)COc1cccc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.47
KDM4E B2RXH2 3/20 0.47
MEN1 O00255 1/20 0.47
CYP2C19 P33261 1/20 0.47
KMT2A Q03164 1/20 0.47
NR2E1 Q9Y466 6/20 0.46
ALDH1A1 P00352 4/20 0.46
HPGD P15428 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
ATM Q13315 1/20 0.44
KCNA3 P22001 1/20 0.43
OGG1 O15527 1/20 0.42
CYP2D6 P10635 4/20 0.41
ADRB2 P07550 3/20 0.41
ADRB1 P08588 3/20 0.41
SLC6A4 P31645 3/20 0.41
HTR2B P41595 3/20 0.41
SIGMAR1 Q99720 3/20 0.41
ADRB3 P13945 2/20 0.41
HTR2A P28223 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4192753 0.96 CYP1A2 (0.44) CYP1A2KDM4EMEN1CYP2C19KMT2A
SCHEMBL1394646 0.95 KDM4E (0.51) CYP1A2KDM4EMEN1CYP2C19KMT2A
SCHEMBL4191192 0.94 KDM4E (0.50) CYP1A2KDM4EMEN1CYP2C19KMT2A
SCHEMBL4190665 0.93 CYP1A2 (0.45) CYP1A2KDM4EMEN1CYP2C19KMT2A
SCHEMBL4204600 0.92 KDM4E (0.43) CYP1A2KDM4EMEN1CYP2C19KMT2A
SCHEMBL4195362 0.90 CYP1A2 (0.47) CYP1A2KDM4EMEN1CYP2C19KMT2A
SCHEMBL18492218 0.89 CYP1A2 (0.55) CYP1A2KDM4EMEN1CYP2C19KMT2A
SCHEMBL13853203 0.89 CYP1A2 (0.41) CYP1A2KDM4EMEN1CYP2C19KMT2A
SCHEMBL13017894 0.85 CYP2D6 (0.37) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL4195601 0.84 PTPN7 (0.44) KDM4EMEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1627867-B1 (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF MITSUI CHEMICALS INC (JP) 2016-01-20 EP disclosed
US-7534909-B2 (Meth) acrylic ester compound and use thereof MITSUI CHEMICALS, INC. (JP) 2009-05-19 US disclosed
US-20070078198-A1 (Meth) acrylic ester compound and use thereof MITSUI CHEMICALS, INC. (JP) 2007-04-05 US disclosed
EP-1627867-A1 (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF Mitsui Chemicals, Inc. (JP) 2006-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078198-A1 (Meth) acrylic ester compound and use thereof METTL14, PAM, TAS2R41 CYP1A2 897/4885KDM4E 270/4885MEN1 744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.